当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy.

Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy.

Abstract：

BACKGROUND:Recent evidence found probiotics could inhibit Helicobacter pylori colonization from both in vitro and in vivo studies. AIM:To systematically evaluate whether adding probiotics to anti-H. pylori regimens could improve eradication rates and reduce side effects during anti-H. pylori treatment. METHODS:Eligible articles were identified by searches of electronic databases. We included all randomized trials comparing probiotics supplementation to placebo or no treatment during anti-H. pylori regimens. Statistical analysis was performed with Review Manager 4.2.8. Subanalysis/Sensitivity analysis was also performed. RESULTS:We identified 14 randomized trials (n = 1671). Pooled H. pylori eradication rates were 83.6% (95% CI = 80.5-86.7%) and 74.8% (95% CI = 71.1-78.5%) for patients with or without probiotics by intention-to-treat analysis, respectively, the odds ratio (OR) was 1.84 (95% CI = 1.34-2.54); the occurrence of total side effects were 24.7% (95% CI = 20.0-29.4%) and 38.5% (95% CI = 33.0-44.1%) for groups with or without probiotics, especially for diarrhoea, the summary OR was 0.44 (95% CI = 0.30-0.66). CONCLUSIONS:Our review suggests that supplementation with probiotics could be effective in increasing eradication rates of anti-H. pylori therapy, and could be considered helpful for patients with eradication failure. Furthermore, probiotics show a positive impact on H. pylori therapy-related side effects.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Tong JL,Ran ZH,Shen J,Zhang CX,Xiao SD

doi

10.1111/j.1365-2036.2006.03179.x

subject

Has Abstract

pub_date

2007-01-15 00:00:00

pages

155-68

issue

2

eissn

0269-2813

issn

1365-2036

pii

APT3179

journal_volume

25

pub_type

杂志文章,meta分析

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • Review article: transcriptional events controlling the terminal differentiation of intestinal endocrine cells.

    abstract：:Secretin-producing enteroendocrine cells arise from a multipotential endocrine progenitor in the crypts of the small intestine. As these cells migrate up the crypt-villus axis, they produce secretin and stop dividing as they terminally differentiate and die. Transcription of the secretin gene is controlled by a comple...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2000.014s1170.x

    authors： Mutoh H,Ratineau C,Ray S,Leiter AB

    更新日期：2000-04-01 00:00:00

  • Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children.

    abstract：AIM:To compare the results of culture and epsilometer test with fluorescence in situ hybridization for the detection of Helicobacter pylori and the presence of clarithromycin-susceptible and clarithromycin-resistant strains in antral biopsies from children. METHODS:Antral biopsies from 149 unselected children were inv...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2002.01382.x

    authors： Feydt-Schmidt A,Rüssmann H,Lehn N,Fischer A,Antoni I,Störk D,Koletzko S

    更新日期：2002-12-01 00:00:00

  • Review article: the incidence and risk factors for irritable bowel syndrome in population-based studies.

    abstract：BACKGROUND:In the absence of prior gastrointestinal infection, the risk factors for irritable bowel syndrome (IBS) are not well established. AIM:To identify the incidence and risk factors for IBS in general population samples METHODS: Narrative review of population-based studies. Electronic databases were searched usi...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.15396

    authors： Creed F

    更新日期：2019-09-01 00:00:00

  • Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.

    abstract：BACKGROUND:Mesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis. AIM:To evaluate the efficacy of mesalazine suppositories in patients with ulcerative colitis (UC) and rectal inflammation; and in patient groups categorised by the extent...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/apt.12362

    authors： Watanabe M,Nishino H,Sameshima Y,Ota A,Nakamura S,Hibi T

    更新日期：2013-08-01 00:00:00

  • An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively.

    abstract：BACKGROUND:The combination of omeprazole and amoxycillin has demonstrated effectiveness with very few side-effects in the treatment of H. pylori infection, however cure rates have varied widely. The present study addresses the question as to the extent to which the cure rate of H. pylori infection depends on the size o...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.1997.140316000.x

    authors： Miehlke S,Mannes GA,Lehn N,Hele C,Stolte M,Bayerdörffer E

    更新日期：1997-04-01 00:00:00

  • Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis.

    abstract：BACKGROUND:The accuracy of symptom-based diagnostic criteria for irritable bowel syndrome (IBS) is modest. AIMS:To derive and validate a new test that utilises latent class analysis. METHODS:Symptom, colonoscopy, and histology data were collected from 1981 patients and 360 patients in two cohorts referred to secondar...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13949

    authors： Sood R,Gracie DJ,Gold MJ,To N,Pinto-Sanchez MI,Bercik P,Moayyedi P,Ford AC,Law GR

    更新日期：2017-03-01 00:00:00

  • Review article: the treatment of fatty liver disease associated with the metabolic syndrome.

    abstract：:The treatment of non-alcoholic fatty liver disease may be worthwhile to prevent progression to advanced liver failure, but no therapy is definitely evidence-based. Weight loss or lifestyle modifications remain the primary line of intervention, particularly in overweight or obese subjects. In adult non-alcoholic fatty ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2005.02593.x

    authors： Marchesini G,Natale S,Manini R,Agostini F

    更新日期：2005-11-01 00:00:00

  • Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease.

    abstract：BACKGROUND:Tacrolimus is a calcineurin inhibitor commonly used for prophylaxis of rejection in renal and liver transplantation. There are limited but favourable data regarding its possible use in patients with inflammatory bowel disease (IBD). AIMS:To evaluate the efficacy and safety of tacrolimus in patients with IBD...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/apt.15687

    authors： Rodríguez-Lago I,Castro-Poceiro J,Fernández-Clotet A,Mesonero F,López-Sanromán A,López-García A,Márquez L,Clos-Parals A,Cañete F,Vicuña M,Nantes Ó,Merino O,Matallana V,Gordillo J,Elorza A,Vicente R,Casanova MJ,Ferreiro-

    更新日期：2020-05-01 00:00:00

  • The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.

    abstract：BACKGROUND:Treatment with interferon-alpha has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events. AIM:To investigate the safety of pegylated interferon alpha-2b in 300 hepatitis B e antigen-positive patients...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2005.02453.x

    authors： van Zonneveld M,Flink HJ,Verhey E,Senturk H,Zeuzem S,Akarca US,Cakaloglu Y,Simon C,So TM,Gerken G,de Man RA,Hansen BE,Schalm SW,Janssen HL,HBV 99-01 Study Group.

    更新日期：2005-05-01 00:00:00

  • Clarithromycin-amoxycillin therapy for Helicobacter pylori infection.

    abstract：BACKGROUND:More convenient therapies are needed to treat Helicobacter pylori infection successfully. Clarithromycin and amoxycillin are effective against H. pylori both in vivo and in vitro. Recent success with a high dose amoxycillin-metronidazole combination therapy led us to evaluate clarithromycin-amoxycillin dual ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1111/j.1365-2036.1994.tb00313.x

    authors： al-Assi MT,Genta RM,Karttunen TJ,Graham DY

    更新日期：1994-08-01 00:00:00

  • Coeliac disease: a biopsy is not always necessary for diagnosis.

    abstract：BACKGROUND:In view of the high diagnostic accuracy of immunoglobulin-A-tissue transglutaminase antibodies for detecting coeliac disease, we have explored whether a small bowel biopsy is always required to establish the diagnosis. AIM:To define the transglutaminase antibody level giving a positive predictive value for ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03609.x

    authors： Hill PG,Holmes GK

    更新日期：2008-04-01 00:00:00

  • Review article: the epidemiology and prevention of gastric cancer.

    abstract：BACKGROUND:Gastric cancer can be divided into cardia and noncardia gastric adenocarcinoma (NCGA). Non cardia gastric cancer is a disease that has declined in global incidence but has remained as an extremely lethal cancer. AIM:To review recent advances in epidemiology and strategies in prevention of non cardia gastric...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.12814

    authors： Fock KM

    更新日期：2014-08-01 00:00:00

  • Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument.

    abstract：BACKGROUND:While current medications used to treat patients with chronic hepatitis C virus (HCV) effectively produce sustained viral response (SVR), postponement of therapy is often times attributed to patient perceptions of unfavourable outcomes. However, an instrument to assess patient perceptions of therapy (i.e. tr...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12202

    authors： Szeinbach SL,Baran RW,Dietz B,Gazzouola Rocca L,Littlefield D,Yawn BP

    更新日期：2013-03-01 00:00:00

  • Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood.

    abstract：BACKGROUND:A lack of reliable treatments for abdominal pain-related functional gastrointestinal disorders prompts interest in new therapies. AIM:To evaluate systematically the effect of Lactobacillus rhamnosus GG (LGG) for treating abdominal pain-related functional gastrointestinal disorders in children. METHODS:MEDL...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1111/j.1365-2036.2011.04665.x

    authors： Horvath A,Dziechciarz P,Szajewska H

    更新日期：2011-06-01 00:00:00

  • Classification of dyspepsia and response to treatment with proton-pump inhibitors.

    abstract：BACKGROUND:Lacking an objective 'gold standard' for diagnosing dyspepsia, several symptom-based classifications have been suggested. AIM:To assess if response to proton-pump inhibitor treatment could provide useful information for current or future dyspepsia classification. METHODS:Post hoc analyses of 829 patients t...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2004.02243.x

    authors： Meineche-Schmidt V

    更新日期：2004-11-15 00:00:00

  • H2-antagonist maintenance therapy versus Helicobacter pylori eradication in patients with chronic duodenal ulcer disease: a prospective study.

    abstract：BACKGROUND:Few outcome studies directly compare Helicobacter pylori eradication therapy with maintenance H2-antagonist therapy in duodenal ulcer disease. AIM:To examine prospectively the efficacy of H. pylori eradication therapy with ranitidine maintenance therapy over 1 year in patients with confirmed chronic duodena...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.1998.00391.x

    authors： Prach AT,Malek M,Tavakoli M,Hopwood D,Senior BW,Murray FE

    更新日期：1998-09-01 00:00:00

  • Randomised clinical trial: enteral nutrition does not improve the long-term outcome of alcoholic cirrhotic patients with jaundice.

    abstract：BACKGROUND:Malnutrition and jaundice are independent prognostic factors in cirrhosis. AIM:To assess the impact of enteral nutrition on the survival of alcoholic cirrhotic patients with jaundice but without acute alcoholic hepatitis. METHODS:The study was a multicentre prospective randomised controlled trial comparing...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2012.05075.x

    authors： Dupont B,Dao T,Joubert C,Dupont-Lucas C,Gloro R,Nguyen-Khac E,Beaujard E,Mathurin P,Vastel E,Musikas M,Ollivier I,Piquet MA

    更新日期：2012-05-01 00:00:00

  • A regional audit of iatrogenic perforation of tumours of the oesophagus and cardia.

    abstract：INTRODUCTION:With the rising incidence of oesophageal cancer, palliative treatment has an increasingly important role. With median survival unlikely to exceed 6 months, in advanced disease the palliative therapy chosen must not hasten patient's demise. AIM:To establish the outcome of both modern and historical palliat...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1365-2036.2005.02324.x

    authors： Jethwa P,Lala A,Powell J,McConkey CC,Gillison EW,Spychal RT

    更新日期：2005-02-15 00:00:00

  • The effect of SK&F 94482 (BMY-25368) on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects.

    abstract：:In a double-blind, placebo-controlled study of SK&F 94482 (BMY-25368) (400-mg, post-evening meal, for 7 days in 11 healthy subjects), there was a significant 75% decrease in median integrated 24-h intragastric acidity during dosing with the drug (218 mmol h/L) compared with placebo (883 mmol h/L; P = 0.003). The singl...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1989.tb00248.x

    authors： Gavey CJ,Smith JT,Nwokolo CU,Pounder RE

    更新日期：1989-12-01 00:00:00

  • Underutilization of gastroprotection for at-risk patients undergoing percutaneous coronary intervention: Spain compared with the United States.

    abstract：BACKGROUND:Proton pump inhibitors (PPIs) are the preferred agents for the prevention of aspirin-associated upper gastrointestinal bleeding (UGIB). Data are limited to determine whether PPIs are being used to reduce UGIB risk. AIM:To evaluate the implementation of PPI treatment to reduce the GI risk in two cardiology c...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1365-2036.2010.04393.x

    authors： Casado-Arroyo R,Scheiman JM,Polo-Tomas M,Saini SD,Del Rio A,Guastello E,Lanas A

    更新日期：2010-09-01 00:00:00

  • Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients.

    abstract：BACKGROUND:Adalimumab, at an induction dose of 160/80 mg followed by 40 mg every other week is approved for treatment of refractory Crohn's disease (CD) and for patients with loss of response to infliximab. AIM:To evaluate the indications for adalimumab, the proportion of inflammatory bowel disease patients who requir...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03878.x

    authors： Swaminath A,Ullman T,Rosen M,Mayer L,Lichtiger S,Abreu MT

    更新日期：2009-02-01 00:00:00

  • Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.

    abstract：BACKGROUND:One-week low-dose proton pump inhibitor-based triple therapies have usually proved to be effective treatments for Helicobacter pylori infection. AIM:To investigate the eradication efficacy, safety profile and patient compliance of two triple therapies containing a standard dose of rabeprazole and a new fluo...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1046/j.1365-2036.2000.00846.x

    authors： Cammarota G,Cianci R,Cannizzaro O,Cuoco L,Pirozzi G,Gasbarrini A,Armuzzi A,Zocco MA,Santarelli L,Arancio F,Gasbarrini G

    更新日期：2000-10-01 00:00:00

  • The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.

    abstract：BACKGROUND:Anti-TNF agents are now widely used in Crohn's disease (CD), and in ulcerative colitis (UC). AIM:To review the safety profile of anti-TNF agents in all patients treated with infliximab in Edinburgh from 1999 to 2007. METHODS:Complete data were available on 202/207 patients comprising 157 CD, 42 UC and thre...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03882.x

    authors： Lees CW,Ali AI,Thompson AI,Ho GT,Forsythe RO,Marquez L,Cochrane CJ,Aitken S,Fennell J,Rogers P,Shand AG,Penman ID,Palmer KR,Wilson DC,Arnott ID,Satsangi J

    更新日期：2009-02-01 00:00:00

  • Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer?

    abstract：BACKGROUND:Triple therapy currently forms the cornerstone of the treatment of patients with Helicobacter pylori-positive duodenal ulcer. AIM:To establish whether prolonged antisecretory therapy is necessary in patients with active duodenal ulcer. METHODS:A total of 77 patients with H. pylori-positive duodenal ulcer w...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2001.01020.x

    authors： Tepes B,Krizman I,Gorensek M,Gubina M,Orel I

    更新日期：2001-07-01 00:00:00

  • Systematic review: managing anaemia in Crohn's disease.

    abstract：BACKGROUND:Anaemia is a serious complication of Crohn's disease that triggers hospitalization and, if not interfered with, may lead to death. AIMS:To systematically summarize and compare the literature on anaemia in Crohn's disease. METHODS:For this systematic review the literature was searched for English-language a...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2006.03146.x

    authors： Kulnigg S,Gasche C

    更新日期：2006-12-01 00:00:00

  • A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.

    abstract：BACKGROUND:Pancreatic enzyme replacement therapy (PERT) is necessary to prevent severe maldigestion and unwanted weight loss associated with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery (PS). AIM:To assess the long-term safety and efficacy of pancrelipase (pancreatin) ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2011.04631.x

    authors： Gubergrits N,Malecka-Panas E,Lehman GA,Vasileva G,Shen Y,Sander-Struckmeier S,Caras S,Whitcomb DC

    更新日期：2011-05-01 00:00:00

  • The significance of histological activity measurements in immune checkpoint inhibitor colitis.

    abstract：BACKGROUND:Colitis is a significant complication of immune checkpoint inhibitors (ICI). Currently, clinical and endoscopic severity are used to guide therapy. AIMS:To investigate associations between clinical, endoscopic, and histological features with outcomes METHODS: We identified 149 patients from seven institutio...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.16142

    authors： Pai RK,Pai RK,Brown I,Choi WT,Schaeffer DF,Farnell D,Kumarasinghe MP,Gunawardena D,Kim BH,Friedman M,Ghayouri M,Lauwers GY

    更新日期：2021-01-01 00:00:00

  • Review article: the management of autoimmune hepatitis beyond consensus guidelines.

    abstract：BACKGROUND:Consensus guidelines aid in the diagnosis and management of autoimmune hepatitis, but they are frequently based on low-quality clinical evidence, conflicting experiences and divergent opinions. Recommendations may be weak, discrepant or non-existent at critical decision points. AIMS:To identify the decision...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.12381

    authors： Czaja AJ

    更新日期：2013-08-01 00:00:00

  • Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease.

    abstract：BACKGROUND:Patients with inflammatory bowel disease (IBD) are at increased risk of osteoporosis. A number of studies have emerged in recent years indicating that tumour necrosis factor (TNF) blockade appears to have a beneficial effect on bone mineral density (BMD) in IBD patients. AIMS:To provide a review of the avai...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2011.04667.x

    authors： Veerappan SG,O'Morain CA,Daly JS,Ryan BM

    更新日期：2011-06-01 00:00:00

  • Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii.

    abstract：BACKGROUND:Saccharomyces boulardii, a well-studied probiotic, can be effective in inflammatory gastrointestinal diseases with diverse pathophysiology, such as inflammatory bowel disease (IBD), and bacterially mediated or enterotoxin-mediated diarrhoea and inflammation. AIM:To discuss the mechanisms of action involved ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2009.04102.x

    authors： Pothoulakis C

    更新日期：2009-10-15 00:00:00